Pacira BioSciences (PCRX) Set to Announce Quarterly Earnings on Wednesday

Pacira BioSciences (NASDAQ:PCRX - Get Free Report) is set to post its quarterly earnings results after the market closes on Wednesday, November 6th. Analysts expect Pacira BioSciences to post earnings of $0.72 per share for the quarter.

Pacira BioSciences (NASDAQ:PCRX - Get Free Report) last announced its earnings results on Tuesday, July 30th. The company reported $0.64 earnings per share for the quarter, topping the consensus estimate of $0.53 by $0.11. Pacira BioSciences had a net margin of 9.21% and a return on equity of 13.22%. The firm had revenue of $178.02 million for the quarter, compared to the consensus estimate of $173.31 million. On average, analysts expect Pacira BioSciences to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Pacira BioSciences Stock Down 1.8 %

PCRX traded down $0.31 during trading hours on Thursday, hitting $16.56. 332,981 shares of the company's stock were exchanged, compared to its average volume of 868,782. Pacira BioSciences has a 12-month low of $11.16 and a 12-month high of $35.95. The firm has a 50 day moving average of $15.29 and a 200 day moving average of $21.42. The firm has a market cap of $770.80 million, a P/E ratio of 11.80 and a beta of 0.84. The company has a current ratio of 6.82, a quick ratio of 5.70 and a debt-to-equity ratio of 0.67.

Insider Activity

In related news, CEO Frank D. Lee bought 8,264 shares of the stock in a transaction dated Monday, August 12th. The stock was acquired at an average price of $12.10 per share, for a total transaction of $99,994.40. Following the acquisition, the chief executive officer now owns 107,784 shares in the company, valued at approximately $1,304,186.40. This represents a 0.00 % increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In the last quarter, insiders purchased 11,176 shares of company stock worth $136,240. Corporate insiders own 6.40% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on PCRX shares. Piper Sandler downgraded shares of Pacira BioSciences from an "overweight" rating to a "neutral" rating and cut their target price for the stock from $42.00 to $11.00 in a research note on Monday, August 12th. Barclays downgraded shares of Pacira BioSciences from an "overweight" rating to an "equal weight" rating and cut their target price for the stock from $38.00 to $25.00 in a research note on Wednesday, July 3rd. Royal Bank of Canada upped their target price on shares of Pacira BioSciences from $14.00 to $15.00 and gave the stock a "sector perform" rating in a research note on Friday, October 4th. Raymond James cut shares of Pacira BioSciences from an "outperform" rating to a "market perform" rating in a report on Monday, August 12th. Finally, StockNews.com cut shares of Pacira BioSciences from a "strong-buy" rating to a "buy" rating in a report on Monday, August 12th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and an average target price of $24.20.

Pacira BioSciences Company Profile

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.